Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise Portfolio News / By admin September 24, 2019 Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise Read More »
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor Portfolio News / By admin September 17, 2019 REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor Read More »
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Portfolio News / By admin September 4, 2019 Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Read More »
Kallyope Inc. Appoints Juha Lauren as Chief Business Officer Portfolio News / By admin September 4, 2019 Kallyope Inc. Appoints Juha Lauren as Chief Business Officer Read More »
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Portfolio News / By admin September 4, 2019 Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Read More »
Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer Portfolio News / By admin September 3, 2019 Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer Read More »
Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy Portfolio News / By admin August 14, 2019 Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy Read More »
ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance Portfolio News / By admin August 8, 2019 ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance Read More »
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer Portfolio News / By admin August 6, 2019 Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer Read More »
Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development Portfolio News / By admin July 17, 2019 Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development Read More »
